From Wall Street to Cell Therapy: Audrey Greenberg’s Journey
June 30, 2025
We sit down with Audrey Greenberg to discuss investment, cell therapy, and what to look for when hiring talent.
6 min read

False
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
After his postdoc, Simon Tasker joined Colorcon as a bench chemist – and never left. Today, he’s the company’s CEO. Here’s how his career unfolded as he grew within the company he now leads.
All the latest Medicine Maker articles.
July 1, 2025
Since the FDA announced plans to phase out mandatory animal testing, in silico drug discovery and development platforms are emerging. Welcome to the age of biosimulation.
6 min read
July 1, 2025
Our latest news roundup reports on thimerosal elimination, subscription termination, depression alleviation, and more
4 min read
June 30, 2025
We ask experts for their views on the GLP-1 market in this exclusive eBook.
1 min read
June 30, 2025
We sit down with Audrey Greenberg to discuss investment, cell therapy, and what to look for when hiring talent.
6 min read
June 27, 2025
Researchers have developed a new way to create covalent peptide inhibitors of transcription factors – proteins once considered “undruggable.”
8 min read
June 27, 2025
Vaccines, mRNA, ADCS, and beyond! Check out our latest eBook where we speak with experts about the trends and challenges in biopharma drug development.
1 min read
June 26, 2025
A look at how nut-derived pharmaceutical ingredients can deliver a sustainable, natural supply of peptides and more.
2 min read
June 26, 2025
Our latest news roundup reports on the Bayer-Tsinghua partnership expansion, GLP-1 diabetes treatments, and GSK EU acceptance of linerixibat.
3 min read
June 25, 2025
Why spray-drying could reduce supply chain costs, address infrastructure challenges, and pave the way for intranasal mRNA vaccine delivery.
5 min read
June 25, 2025
Learning more about the people behind the Power List 2025.
5 min read
False